Novo Nordisk's biggest revenue contributor in the third quarter, Simeglutide, made its debut at the CIIE
王俊杰2017
发表于 2024-11-7 14:06:06
134
0
0
Novo Nordisk's third quarter report once again shows the industry the market potential of the star product Smeaglutide. On November 6th, Novo Nordisk released its third quarter report showing a year-on-year revenue growth of 23%, with the largest growth driven by semaglutide, accounting for 69% of Novo Nordisk's revenue. At the same time as the global release of its third quarter report, Novo Nordisk is showcasing its major product, semaglutide, at the CIIE. The first exhibition in China includes the world's first and currently only GLP-1 receptor agonist, semaglutide tablets (trade name: Novozymes), and the world's first GLP-1 weekly formulation for long-term weight management, Novozymes, also known as semaglutide injection for long-term weight management.
Zhou Xiaping, Senior Vice President of Novo Nordisk Global and President of Greater China, stated that Novo Nordisk has been continuously leading the research and development breakthroughs of GLP-1 drugs. At this CIIE, Novo Nordisk launched the "Healthy China Action - Metabolic Renewal Year" campaign. Through the CIIE platform, Novo Nordisk has witnessed numerous innovative drugs accelerating their landing in China and even obtaining approval simultaneously, completing the transformation from "exhibits" to "commodities", and also achieving pioneering innovation in public science education.
In addition, in terms of financial reports, in a single quarter, Novo Nordisk's third quarter revenue was 71.311 billion Danish kroner, a year-on-year increase of 22%, and net profit was 27.301 billion Danish kroner, a year-on-year increase of 21%, higher than market expectations. Affected by the above news, Novo Nordisk rose by over 6% before the stock market opened on November 6th. Overall, in the first three quarters, Novo Nordisk's revenue was KRK 204.72 billion, a year-on-year increase of 23%; Net profit was 72.758 billion Danish kroner, an increase of 18% year-on-year.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Caterpillar's sales and revenue for the third quarter were $16.1 billion, a year-on-year decrease of 4%
- Weibo Q3 revenue of 3.294 billion yuan, adjusted operating profit of 1.159 billion yuan
- Xiaopeng Motors' third quarter revenue growth is 18.4%, and delivery volume in November is expected to exceed 30000 vehicles
- NIO: Q3 revenue of 18.67 billion yuan, up 7.0% month on month
- All Things New Life (Love Recycling) achieved a revenue of 4.05 billion yuan in the third quarter, with non GAAP operating profit exceeding 100 million yuan
- Selling more and losing more? NIO's third quarter revenue decreased by 2.1% year-on-year, with an adjusted net loss of 4.413 billion yuan
- Nvidia's third quarter revenue reached $35.082 billion
- Under revenue pressure, iQiyi will invest more resources in operating micro dramas
- Pinduoduo's Q3 revenue was 99.4 billion yuan, and it continues to increase investment in the construction of "new quality supply" and "e-commerce westward"
- The revenue growth rate of Greater China region exceeds 50%. Amalfin Sports turned losses in the first three quarters and searched for the next "ancestor bird"
-
米東時間の金曜日、米株3大指数は集団で上昇し、終値を締め切ると、ダウは0.97%上昇し、今週は1.96%上昇した。納指は0.16%上昇し、今週は1.73%上昇した。スタンダード500指数は0.35%上昇し、今週は1.68%上昇した。 ...
- leekhy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
イランは現地時間の金曜日(11月22日)、国際原子力機関(IAEA)がイランに圧力をかけている新たな決議に応えるため、大量の遠心分離機を追加してウラン濃縮を行うと発表した。 IAEA理事会は木曜日、イランの協力不 ...
- 1900_后
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
蔚来法務部は11月22日、インターネット上に流出した蔚来と他の企業の資本レベルのデマについて、会社が最初に通報し、受理されたと発表した。会社はすでにこのデマの全リンク推進過程と、マルチプラットフォームが ...
- 愿为素心人
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
「リハビリのビッグデータの利点とAIの力を借りて、専門監督、リハビリ師が子供に個性的なリハビリを提供し、この専門能力をAIを通じて特殊需要児リハビリ業界全体に放射することができれば、受益した子供の数は計 ...
- 哈耶萨鲁亚源
- 3 天前
- 支持
- 反对
- 回复
- 收藏